Skip to main content
. 2014 Mar 14;69(7):1938–1944. doi: 10.1093/jac/dku052

Table 2.

Regression analysis of effect of de novo mutations on FC to NNRTIs (cABC arm)

Mutation na (%) Nevirapine univariate
Efavirenz univariate
Etravirine
univariate
multivariateb
relative change (95% CI) P value relative change (95% CI) P value relative change (95% CI) P value relative change (95% CI) P value
No. of TAMs
 0 8 (23) 1.0 0.78 1.0 0.17 1.0 0.01 1.0 <0.001
 1–2 9 (26) 0.87 (0.37, 2.03) 0.62 (0.37, 1.06) 0.51 (0.33, 0.80) 0.47 (0.30, 0.71)
 ≥3 18 (51) 0.77 (0.37, 1.62) 0.69 (0.44, 1.10) 0.60 (0.41, 0.88) 0.49 (0.34, 0.71)
K65R 1 (3) 1.04 (0.18, 6.03) 0.96 1.13 (0.36, 3.54) 0.83 0.99 (0.35, 2.82) 0.99 0.32 (0.12, 0.84) 0.02
69ins 1 (3) 0.53 (0.09, 3.04) 0.47 0.66 (0.21, 2.04) 0.45 0.97 (0.34, 2.76) 0.96
L74V 1 (3) 1.31 (0.23, 7.57) 0.75 1.34 (0.43, 4.20) 0.60 1.28 (0.45, 3.61) 0.64
Y115F 4 (11) 0.89 (0.35, 2.22) 0.79 1.10 (0.60, 2.00) 0.75 0.68 (0.40, 1.15) 0.15 0.62 (0.38, 1.00) 0.05
M184V 31 (89) 0.90 (0.36, 2.24) 0.81 0.63 (0.36, 1.13) 0.12 0.45 (0.28, 0.73) 0.002
N348I 5 (14) 1.10 (0.48, 2.53) 0.82 1.00 (0.58, 1.73) 0.99 1.30 (0.80, 2.12) 0.28 1.77 (1.14, 2.77) 0.01
A360IV 3 (9) 2.09 (0.76, 5.75) 0.15 1.16 (0.59, 2.30) 0.65 1.01 (0.54, 1.88) 0.97
E399D 1 (3) 0.76 (0.13, 4.38) 0.75 0.59 (0.19, 1.83) 0.35 0.65 (0.23, 1.82) 0.40

aNumber of patients in whom a mutation was observed at week 96 that was not observed at week 0.

bA backwards stepwise approach was used, starting with all variables (see the Methods section).